View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. MediSapiens
23 January 2018

Innatoss and MediSapiens Receive EU Grant to Personalise Lyme Diagnostics

Innatoss Laboratories and MediSapiens have partnered to develop a novel Lyme borreliosis (LB) diagnostic interpretation and communication solution.

Innaross is a Dutch company specialised in diagnostics of infectious diseases, while MediSapiens is a developer and provider of genomic, biomedical and health data solutions.

The development is supported by the Personalised Medicine Innovation through Digital Enterprise Solutions (PERMIDES) project, funded by the EU.

The partnership aims to develop a novel solution for analysing and reporting LB diagnostics results in a convenient and readily comprehensible manner. The diagnostics of LB is complex, and often requires multiple different parallel and subsequent tests.

Untreated LB can lead to serious health problems. Communicating the results in an easily understandable and actionable manner is pivotal for timely clinical decision-making.

CEO of Innatoss Anja Garritsen says: “For the interpretation of Lyme test results, it is essential to combine the results of multiple tests from different manufacturers. A comparison with previous tests is often essential.

“With the support of PERMIDES, we will create a database that facilitates the analysis and presentation of multiple test results in a user-friendly manner. Innatoss sees such a personalised Lyme dossier as a sound basis to support treatment decisions.”

CCO of MediSapiens Marko Kuisma says: “We should be paying much more attention to how information that affects clinical decision making is conveyed.

“The work we are doing with Innatoss is highly important. We are glad to have the opportunity to work with a leading European LB diagnostics provider, and look forward to bringing new innovations to clinical practice.”

This document demonstrates an example Medisapiens report. It focuses on the gene PTPRK.
Identifying fusion genes from paired-end ribonucleic acid (rna) sequencing (rna-seq) data has the advantage that only expressed fusion genes will be found.
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology